Poor
Not Aligned
Patient Risk:
Low
Summary
Partially matches label content for basic description/mechanism and some contraindications/adverse reaction categories, but includes multiple label-unsupported claims (notably weight-management indication, FDA approval dates, and several 'common side effects' items) and omits major safety/dosing/prescribing elements (boxed warning specificity, dosing cautions, pregnancy and pediatric use).
Category Scores
Accurate Statements
Mounjaro is a medication containing the active ingredient tirzepatide.
11 DESCRIPTION
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist.
11 DESCRIPTION
Tirzepatide works by activating GIP receptors.
11 DESCRIPTION
Tirzepatide works by activating GLP-1 receptors.
11 DESCRIPTION
More serious side effects of Mounjaro can include pancreatitis.
6 ADVERSE REACTIONS
More serious side effects of Mounjaro can include gallbladder problems.
6 ADVERSE REACTIONS
More serious side effects of Mounjaro can include kidney problems.
6 ADVERSE REACTIONS
More serious side effects of Mounjaro can include certain types of thyroid tumors.
6 ADVERSE REACTIONS; 14 CLINICAL STUDIES (WARNING)
Patients with a history of medullary thyroid carcinoma should not use Mounjaro.
4 CONTRAINDICATIONS; 14 CLINICAL STUDIES (WARNING)
Patients with Multiple Endocrine Neoplasia syndrome type 2 should not use Mounjaro.
4 CONTRAINDICATIONS; 14 CLINICAL STUDIES (WARNING)
Unsupported Statements
Tirzepatide promotes weight loss.
Not supported by the provided label sections.
Mounjaro is indicated for chronic weight management in adults who are obese or overweight and have at least one weight-related comorbidity.
Not supported by the provided label sections.
The FDA approved Mounjaro for the treatment of type 2 diabetes in May 2022.
FDA approval date is not supported by the provided label sections.
The FDA granted approval for chronic weight management for Mounjaro in November 2023.
FDA approval date is not supported by the provided label sections.
Common side effects of Mounjaro include nausea.
Not supported by the provided label sections.
Common side effects of Mounjaro include vomiting.
Not supported by the provided label sections.
Common side effects of Mounjaro include diarrhea.
Not supported by the provided label sections.
Common side effects of Mounjaro include decreased appetite.
Not supported by the provided label sections.
Common side effects of Mounjaro include constipation.
Not supported by the provided label sections.
Common side effects of Mounjaro include abdominal pain.
Not supported by the provided label sections.
Contradictions
Important Omissions
Boxed warning content/specific boxed-warning language and associated prescribing cautions were not addressed.
Importance:
High
Dosage and administration details (including titration/dose escalation and missed-dose or administration specifics) were not provided.
Importance:
High
Key warnings and precautions beyond thyroid tumors (e.g., hypoglycemia with concomitant insulin secretagogues/insulin; acute kidney injury due to volume depletion; severe gastrointestinal reactions; diabetic retinopathy complications; acute gallbladder disease) were not detailed.
Importance:
High
Use in specific populations (pregnancy/lactation; pediatric use) was not addressed.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
While several mechanistic and some serious-risk/category items and contraindications align with the provided label excerpts, multiple label-unsupported 'common side effects' and non-label-anchored indication/approval claims reduce reliability. High-risk prescribing domains (boxed-warning specificity, dosing cautions, pregnancy/pediatric sections) were omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported label claims (weight-management indication, FDA approval dates, and several 'common side effects') plus major omissions of key boxed warning/dosing/specific-population elements.
Suggested Improvement
Restrict statements to supported label sections; remove approval-date and weight-management indication claims unless present in the provided label; cite only provided label sections; add boxed-warning language/safety counseling and include dosing and specific-population (pregnancy/pediatric) information as applicable.